Skip to content

Higher diagnostic accuracy and cost-effectiveness using a novel biomarker for Treatment in Emergency Medicine Patients with fever

Higher diagnostic accuracy and cost-effectiveness using a novel biomarker for Treatment in Emergency Medicine Patients with fever - HiTEMP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41410
Enrollment
550
Registered
2014-08-12
Start date
2014-08-18
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fever pyrexia

Interventions

Patients will be allocated into two groups: 1. A control group (standard-of-care) 2. Intervention group (PCT-guided therapy)

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: fever

Exclusion criteria

Exclusion criteria: under 18 years of age. Pregnant patients. Immunocompromised patients (neutropenia, defined as an absolute neutrophil count less than 0.5x109/L, current chemotherapy, transplantation patients), predetermined illness with an expected death within 24 hours. Surgical fever, defined as fever within 72 hours post-surgery, or patients with a primary surgical diagnosis.

Design outcomes

Primary

MeasureTime frame
* Number of febrile patients who are prescribed antibiotics in the ED * A composite endpoint for safety of PCT-guided therapy, defined as 30 days mortality, Intensive Care Unit (ICU) admittance, or a return visit to the ED within 14 days. * Accuracy of PCT and CRP as area under curve (AUC), compared with the diagnosis of infection by culture, polymerase chain reaction (PCR) and serology.

Secondary

MeasureTime frame
* Hospital treatment costs. (Costs of PCT testing (treatment group only), antibiotics, and other related medical consumption during admittance). * Costs of length of hospital stay (hospitalized patients) or length of ICU stay (critically ill patients). * Related medical consumption during follow-up. (General practitioner (GP) and additional hospital visits, diagnostics and medication) * Days absence from work and reduced productivity while at work. (if applicable) * Costs of extramural type and duration of antimicrobial therapy.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)